Fair Game: How Valeant Cashed In Twice on Higher Drug Prices

It wasn’t just soaring drug prices that helped Valeant Pharmaceuticals’ cash flow. A credit for inventories at those higher prices also plumped the figures.

from NYT > Health http://ift.tt/2aE8QiP
via health&fitness